The DOI matches its Crossref record; 587 of the 587 references it cites were found in a registry or an index.
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Open accessAbstract
Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
Items 201–400 of 587
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Arabi, L., Badiee, A., Mosaffa, F., & Jaafari, M. R. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.044 · Cited by 183
Esser, L., Zhou, F., Pluchino, K. M., Shiloach, J., Ma, J., Tang, W.-K., Gutierrez, C., Zhang, A., Shukla, S., Madigan, J. P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755884 · Cited by 182
Ma, X., Chen, Z., Hua, D., He, D., Wang, L., Zhang, P., Wang, J., Cai, Y., Gao, C., Zhang, X., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400272111 · Cited by 180
Snapshots of ligand entry, malleable binding and induced helical movement in P-glycoprotein
Szewczyk, P., Tao, H., McGrath, A. P., Villaluz, M., Rees, S. D., Lee, S. C., Doshi, R., Urbatsch, I. L., Zhang, Q., & Chang, G. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715000978 · Cited by 180
Bent, E. H., Gilbert, L. A., & Hemann, M. T. (2016) · Genes & Development · doi:10.1101/gad.284851.116 · Cited by 179
Overview of Tumor Cell Chemoresistance Mechanisms
Gatti, L., & Zunino, F. (2005) · Chemosensitivity · doi:10.1385/1-59259-889-7:127 · Cited by 179
Site and sequence specificity of the daunomycin-DNA interaction
Chaires, J. B., Fox, K. R., Herrera, J. E., Britt, M., & Waring, M. J. (1987) · Biochemistry · doi:10.1021/bi00399a031 · Cited by 178
Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells
Nicoletto, R. E., & Ofner, C. M. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04400-y · Cited by 178
Antitopoisomerase drug action and resistance
Nitiss, J. L., & Beck, W. T. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00056-1 · Cited by 177
Antitumour Anthracyclines: Progress and Perspectives
Martins‐Teixeira, M. B., & Carvalho, I. (2020) · ChemMedChem · doi:10.1002/cmdc.202000131 · Cited by 175
Rios-Doria, J., Durham, N., Wetzel, L., Rothstein, R., Chesebrough, J., Holoweckyj, N., Zhao, W., Leow, C. C., & Hollingsworth, R. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.004 · Cited by 174
Zhao, N., Wang, R., Zhou, L., Zhu, Y., Gong, J., & Zhuang, S.-M. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-35 · Cited by 173
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters
Okabe, M., Szakács, G., Reimers, M. A., Suzuki, T., Hall, M. D., Abe, T., Weinstein, J. N., & Gottesman, M. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0539 · Cited by 173
Liu, Y., Fang, J., Kim, Y.-J., Wong, M. K., & Wang, P. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5000373 · Cited by 172
Towards the overcoming of anticancer drug resistance mediated by p53 mutations
Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 172
Petrosillo, G., Ruggiero, F. M., Pistolese, M., & Paradies, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407500200 · Cited by 171
A role for ceramide in driving cancer cell resistance to doxorubicin
Liu, Y., Yu, J. Y., Yin, D., Patwardhan, G. A., Gupta, V. K., Hirabayashi, Y., Holleran, W. M., Giuliano, A. E., Jazwinski, S. M., Gouazé‐Andersson, V., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-092981 · Cited by 170
Hui, R. C.-Y., Gomes, A., Constantinidou, D., Costa, J. R., Karadedou, C. T., de Mattos, S. F., Wymann, M. P., Brosens, J. J., Schulze, A., & Lam, E. W. ‐. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01265-07 · Cited by 170
The UCSF-FDA TransPortal: A Public Drug Transporter Database
Morrissey, K. M., Wen, C. C., Johns, S. J., Zhang, L., Huang, S.-M., & Giacomini, K. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.44 · Cited by 169
Bindra, R. S., & Glazer, P. M. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.03.013 · Cited by 168
Tagami, T., Ernsting, M. J., & Li, S.-D. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.009 · Cited by 166
Chen, H.-C., Jeng, Y.-M., Yuan, R.-H., Hsu, H.-C., & Chen, Y.-L. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2159-4 · Cited by 165
MicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN
Wang, Z.-X., Lu, B.-B., Wang, H., Cheng, Z.-X., & Yin, Y.-M. (2011) · Archives of Medical Research · doi:10.1016/j.arcmed.2011.06.008 · Cited by 164
Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes
Galletti, E., Magnani, M., Renzulli, M. L., & Botta, M. (2007) · ChemMedChem · doi:10.1002/cmdc.200600308 · Cited by 164
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Tavora, B., Reynolds, L. E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D. M., Wong, P.-P., Alexopoulou, A., Elia, G., et al. (2014) · Nature · doi:10.1038/nature13541 · Cited by 163
Adverse Effects of Doxorubicin and Its Metabolic Product on Cardiac RyR2 and SERCA2A
Hanna, A. D., Lam, A., Tham, S., Dulhunty, A. F., & Beard, N. A. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093849 · Cited by 163
MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
Gao, L., Guo, Q., Li, X., Yang, X., Ni, H., Wang, T., Zhao, Q., Liu, H., Xing, Y., Xi, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.034 · Cited by 163
Delessard, M., Saulnier, J., Rives‐Feraille, A., Dumont, L., Rondanino, C., & Rives, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041454 · Cited by 163
Chapuy, B., Koch, R., Radunski, U., Corsham, S., Cheong, N., Inagaki, N., Ban, N., Wenzel, D., Reinhardt, D., Zapf, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.103 · Cited by 162
Xu, L., Beckebaum, S., Iacob, S., Wu, G., Kaiser, G. M., Radtke, A., Liu, C., Kabar, I., Schmidt, H. H., Zhang, X., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.10.028 · Cited by 162
Structural plasticity of single chromatin fibers revealed by torsional manipulation
Bancaud, A., Conde e Silva, N., Barbi, M., Wagner, G., Allemand, J.-F., Mozziconacci, J., Lavelle, C., Croquette, V., Victor, J.-M., Prunell, A., et al. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1087 · Cited by 161
Uncoupling DNA damage from chromatin damage to detoxify doxorubicin
Qiao, X., van der Zanden, S. Y., Wander, D. P. A., Borràs, D. M., Song, J.-Y., Li, X., van Duikeren, S., van Gils, N., Rutten, A., van Herwaarden, T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922072117 · Cited by 161
Ibrahim, M., Abuwatfa, W. H., Awad, N. S., Sabouni, R., & Husseini, G. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020254 · Cited by 161
Zong, T., Mei, L., Gao, H., Cai, W., Zhu, P., Shi, K., Chen, J., Wang, Y., Gao, F., & He, Q. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500057n · Cited by 160
Oncogenic Wip1 Phosphatase Is Inhibited by miR-16 in the DNA Damage Signaling Pathway
Zhang, X., Wan, G., Mlotshwa, S., Vance, V. B., Berger, F. G., Chen, H., & Lu, X. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0697 · Cited by 160
Multimodal transfer of MDR by exosomes in human osteosarcoma
Torreggiani, E., Roncuzzi, L., Perut, F., Zini, N., & Baldini, N. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3509 · Cited by 160
Oocyte DNA damage quality control requires consecutive interplay of CHK2 and CK1 to activate p63
Tuppi, M., Kehrloesser, S., Coutandin, D. W., Rossi, V., Luh, L. M., Strubel, A., Hötte, K., Hoffmeister, M., Schäfer, B., De Oliveira, T., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0035-7 · Cited by 160
Reichardt, P., Tabone, M.-D., Mora, J., Morland, B., & Jones, R. L. (2018) · Future Oncology · doi:10.2217/fon-2018-0210 · Cited by 160
Serrano, J., Palmeira, C. M., Kuehl, D. W., & Wallace, K. B. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(99)00011-0 · Cited by 159
Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer
Chen, J., Tian, W., Cai, H., He, H., & Deng, Y. (2011) · Medical Oncology · doi:10.1007/s12032-011-0117-4 · Cited by 158
Kato, S., Burke, P., Koch, T. H., & Bierbaum, V. M. (2001) · Analytical Chemistry · doi:10.1021/ac001498q · Cited by 157
Exosomal Doxorubicin Reduces the Cardiac Toxicity of Doxorubicin
Toffoli, G., Hadla, M., Corona, G., Caligiuri, I., Palazzolo, S., Semeraro, S., Gamini, A., Canzonieri, V., & Rizzolio, F. (2015) · Nanomedicine · doi:10.2217/nnm.15.118 · Cited by 156
Regulation of Programmed Cell Death by NF-κB and its Role in Tumorigenesis and Therapy
Fan, Y., Dutta, J., Gupta, N., Fan, G., & Gélinas, C. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_11 · Cited by 156
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Self-citationAdipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin
Sheng, X., Parmentier, J., Tucci, J., Pei, H., Cortez-Toledo, O., Dieli-Conwright, C. M., Oberley, M. J., Neely, M. N., Orgel, E., Louie, S. G., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0338 · Cited by 156
Characterization of the organic cation transporter SLC22A16: A doxorubicin importer
Okabe, M., Unno, M., Harigae, H., Kaku, M., Okitsu, Y., Sasaki, T., Mizoi, T., Shiiba, K., Takanaga, H., Terasaki, T., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.174 · Cited by 154
Nooter, K., de la Rivière, G. B., Look, M. P., van Wingerden, K. E., Henzen-Logmans, S. C., Scheper, R. J., Flens, M. J., Klijn, J. G. M., Stoter, G., & Foekens, J. A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.414 · Cited by 153
Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity
Sishi, B., Loos, B., van Rooyen, J., & Engelbrecht, A. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.005 · Cited by 153
Ho, K.-K., McGuire, V. A., Koo, C.-Y., Muir, K., de Olano, N., Maifoshie, E., Kelly, D. J., McGovern, U., Monteiro, L. J., Gomes, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.284224 · Cited by 152
Hou, M., Chrysis, D., Nurmio, M., Parvinen, M., Eksborg, S., Söder, O., & Jahnukainen, K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2004 · Cited by 152
NADPH oxidases participate to doxorubicin-induced cardiac myocyte apoptosis
Gilleron, M., Marechal, X., Montaigne, D., Franczak, J., Nevière, R., & Lancel, S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.085 · Cited by 149
Dalmark, M., & Storm, H. H. (1981) · The Journal of General Physiology · doi:10.1085/jgp.78.4.349 · Cited by 148
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
Meshinchi, S., Stirewalt, D. L., Alonzo, T. A., Zhang, Q., Sweetser, D. A., Woods, W. G., Bernstein, I. D., Arceci, R. J., & Radich, J. P. (2003) · Blood · doi:10.1182/blood-2003-01-0137 · Cited by 146
Topoisomerase II and the etiology of chromosomal translocations
Felix, C. A., Kolaris, C. P., & Osheroff, N. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.031 · Cited by 145
Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Edwardson, D. W., Narendrula, R., Chewchuk, S., Mispel-Beyer, K., Mapletoft, J., & Parissenti, A. M. (2015) · Current Drug Metabolism · doi:10.2174/1389200216888150915112039 · Cited by 145
Bartlett, J. J., Trivedi, P. C., Yeung, P. K. F., Kienesberger, P. C., & Pulinilkunnil, T. (2016) · Biochemical Journal · doi:10.1042/bcj20160385 · Cited by 145
Vilaboa, N. E., Galán, A., Troyano, A., de Blas, E., & Aller, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909136199 · Cited by 144
Koch, R., Aung, T., Vogel, D., Chapuy, B., Wenzel, D., Becker, S., Sinzig, U., Venkataramani, V., von Mach, T., Jacob, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0577 · Cited by 142
Lehuédé, C., Li, X., Dauvillier, S., Vaysse, C., Franchet, C., Clement, E., Estève, D., Longué, M., Chaltiel, L., Gonidec, S. L., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1088-6 · Cited by 142
Lakkakula, J., Gujarathi, P., Pansare, P., & Tripathi, S. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.117696 · Cited by 141
Taatjes, D. J., Gaudiano, G., Resing, K. A., & Koch, T. H. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960835d · Cited by 140
P‐glycoprotein: So Many Ways to Turn It On
Callaghan, R., Crowley, E. H., Biochem, M., Potter, S., & Kerr, I. D. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007311568 · Cited by 140
Chen, Z., Pan, T., Jiang, D., Jin, L., Geng, Y., Feng, X., Shen, A., & Zhang, L. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.01.030 · Cited by 140
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy
Abrams, S. L., Steelman, L. S., Shelton, J. G., Wong, E. W. T., Chappell, W. H., Bäsecke, J., Stivala, F., Donia, M., Nicoletti, F., Libra, M., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11483 · Cited by 137
Nucleosome Chiral Transition under Positive Torsional Stress in Single Chromatin Fibers
Bancaud, A., Wagner, G., Silva, N. C. E., Lavelle, C., Wong, H., Mozziconacci, J., Barbi, M., Sivolob, A., Cam, É. L., Mouawad, L., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.037 · Cited by 137
Substrate and product specificities of SET domain methyltransferases
Rizzo, P. A. D., & Trievel, R. C. (2011) · Epigenetics · doi:10.4161/epi.6.9.16069 · Cited by 136
Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs
Ashley, N., & Poulton, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.11.059 · Cited by 134
Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1)
He, S.-M., Li, R., Kanwar, J. R., & Zhou, S.-F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794839197 · Cited by 133
When apoptosis meets autophagy: deciding cell fate after trauma and sepsis
Hsieh, Y., Athar, M., & Chaudry, I. H. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.002 · Cited by 132
Puca, R., Nardinocchi, L., Porru, M., Simon, A. J., Rechavi, G., Leonetti, C., Givol, D., & D’Orazi, G. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15642 · Cited by 131
miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer
Hu, Y., Qiu, Y., Yagüe, E., Ji, W., Liu, J., & Zhang, J. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.194 · Cited by 131
Abd-Ellatef, G. E. F., Gazzano, E., Chirio, D., Hamed, A. R., Belisario, D. C., Zuddas, C., Peira, E., Rolando, B., Kopecka, J., Marie, M. A. S., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020096 · Cited by 131
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
Gao, L., Wu, Z., Assaraf, Y. G., Chen, Z., & Wang, L. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100770 · Cited by 131
Lv, X., Yu, X., Wang, Y., Wang, F., Li, H., Wang, Y., Lu, D., Qi, R., & Wang, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047351 · Cited by 130
Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance
Zhao, Y., Huan, M., Liu, M., Cheng, Y., Sun, Y., Cui, H., Liu, D., Mei, Q., & Zhou, S. (2016) · Scientific Reports · doi:10.1038/srep35267 · Cited by 130
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents
Cowell, I. G., & Austin, C. A. (2012) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph9062075 · Cited by 129
Expression of a human multidrug resistance gene in ovarian carcinomas.
Bourhis, J., Goldstein, L. J., RIOU, G. F., Pastan, I. H., Gottesman, M. M., & Bénard, J. (1989) · PubMed · Cited by 129
Piya, S., Kornblau, S. M., Ruvolo, V. R., Mu, H., Ruvolo, P. P., McQueen, T. J., Davis, R. E., Hail, N., Kantarjian, H. M., Andreeff, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-692244 · Cited by 128
ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial Genome
Elliott, A. M., & Al‐Hajj, M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0235 · Cited by 127
Tsuchiya, N., Izumiya, M., Ogata‐Kawata, H., Okamoto, K., Fujiwara, Y., Nakai, M., Okabe, A., Schetter, A. J., Bowman, E. D., Midorikawa, Y., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2475 · Cited by 127
Bram, E. E., Stark, M., Raz, S., & Assaraf, Y. G. (2009) · Neoplasia · doi:10.1593/neo.91314 · Cited by 126
Doxorubicin Enhances Nucleosome Turnover around Promoters
Yang, F., Kemp, C. J., & Henikoff, S. (2013) · Current Biology · doi:10.1016/j.cub.2013.03.043 · Cited by 126
Foxo3a Regulates Apoptosis by Negatively Targeting miR-21
Wang, K., & Li, P.-F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.093005 · Cited by 125
Shin, H., Kwon, H., Lee, J.-H., Gui, X., Achek, A., Kim, J. H., & Choi, S. (2015) · Scientific Reports · doi:10.1038/srep15798 · Cited by 124
Broekemeier, K. M., & Pfeiffer, D. R. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92174-8 · Cited by 123
Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review
Peter, S., Alven, S., Maseko, R. B., & Aderibigbe, B. A. (2022) · Molecules · doi:10.3390/molecules27144478 · Cited by 123
Reynolds, J. G., Geretti, E., Hendriks, B. S., Lee, H., Leonard, S. C., Klinz, S. G., Noble, C. O., Lücker, P. B., Zandstra, P. W., Drummond, D. C., et al. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.04.008 · Cited by 122
MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells
Yang, T., Zheng, Z., Li, X., Li, Z.-F., Wang, Y., Geng, Y.-F., Li, B., & Zhang, X. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213497321 · Cited by 121
Anthracyclines: biosynthesis, engineering and clinical applications
Hulst, M. B., Grocholski, T., Neefjes, J., van Wezel, G. P., & Metsä‐Ketelä, M. (2021) · Natural Product Reports · doi:10.1039/d1np00059d · Cited by 117
Michieli, M., Damiani, D., Ermacora, A., Masolini, P., Raspadori, D., Visani, G., Scheper, R. J., & Baccarani, M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01172.x · Cited by 116
Wang, Z., Yu, Y., Dai, W., Lu, J., Cui, J., Wu, H., Yuan, L., Zhang, H., Wang, X., Wang, J., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.08.031 · Cited by 116
XU, R., Liu, S., CHEN, H., & Lao, L. (2015) · Oncology Reports · doi:10.3892/or.2015.4497 · Cited by 115
Wen, C., Fu, L., Huang, J., Dai, Y., Wang, B., Xu, G., Wu, L., & Zhou, H. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10180 · Cited by 115
Al-Jamal, W. T., Al-Ahmady, Z. S., & Kostarelos, K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.03.018 · Cited by 114
Solem, L. E., Heller, L. J., & Wallace, K. B. (1996) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1996.0095 · Cited by 111
Wei, W., Chua, M., Grepper, S., & So, S. K. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-16 · Cited by 110
Novel Extracellular Vesicles Mediate an ABCG2-Dependent Anticancer Drug Sequestration and Resistance
Ifergan, I., Scheffer, G. L., & Assaraf, Y. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2021 · Cited by 110
Human ferritin for tumor detection and therapy
Fan, K., Gao, L., & Yan, X. (2013) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1221 · Cited by 110
Tada, Y., Wada, M., Migita, T., Nagayama, J., Hinoshita, E., Mochida, Y., Maehara, Y., Tsuneyoshi, M., Kuwano, M., & Naito, S. (2002) · International Journal of Cancer · doi:10.1002/ijc.10246 · Cited by 109
Zhang, F.-F., Zhu, Y., Zhao, Q., Yang, D., Dong, Y., Li, J., Xing, W.-X., Li, X., Xing, H., Shi, M., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.05.026 · Cited by 108
Lin, C., Whang, E. E., Donner, D. B., Du, J., Lorch, J. H., He, F., Jiang, X., Price, B. D., Moore, F. D., & Ruan, D. T. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0162 · Cited by 108
Kim, D., Jung, K. H., Lee, D., Yoon, J.-H., Choi, K. S., Kwon, S. W., Shen, H., Morgan, M. J., Hong, S., & Kim, Y. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2034 · Cited by 108
Zhou, D.-C., Zittoun, R., & Marie, J. (1995) · PubMed · Cited by 107
Zhou, Y., Liang, C., Xue, F., Chen, W., Zhi, X., Feng, X., Bai, X., & Liang, T. (2015) · Oncotarget · doi:10.18632/oncotarget.3585 · Cited by 107
Nunn, C. M., Meervelt, L. V., Zhang, S., Moore, M. H., & Kennard, O. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90203-i · Cited by 107
Tabe, Y., Konopleva, M. Y., Contractor, R., Munsell, M. F., Schober, W. D., Jin, L., Tsutsumi‐Ishii, Y., Nagaoka, I., Igari, J., & Andreeff, M. (2005) · Blood · doi:10.1182/blood-2004-10-4126 · Cited by 106
van der Kolk, D. M., de Vries, E. G. E., Putten, W. J. V., Verdonck, L. F., Ossenkoppele, G. J., Verhoef, G. E. G., & Vellenga, E. (2000) · PubMed · Cited by 105
Chen, J., Gomes, A., Monteiro, L. J., Wong, S. Y., Wu, L. H., Ng, T.-T., Karadedou, C. T., Millour, J., Ip, Y.-C., Cheung, Y.-N., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012293 · Cited by 105
Wang, H., Agarwal, P., Zhao, S., Yu, J., Lu, X., & He, X. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.030 · Cited by 105
Kong, J. N., He, Q., Wang, G., Dasgupta, S., Dinkins, M. B., Zhu, G., Kim, A., Spassieva, S. D., & Bieberich, E. (2015) · International Journal of Cancer · doi:10.1002/ijc.29542 · Cited by 104
Heibein, A. D., Guo, B., Sprowl, J. A., MacLean, D. A., & Parissenti, A. M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-381 · Cited by 104
Bacterial Inactivation of the Anticancer Drug Doxorubicin
Westman, E. L., Canova, M. J., Radhi, I. J., Koteva, K. K., Kireeva, I., Waglechner, N., & Wright, G. D. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.011 · Cited by 104
Lal, S., Wong, Z. W., Jada, S. R., Xiang, X., Shu, X. C., Ang, P., Figg, W. D., Lee, E. J., & Chowbay, B. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.6.567 · Cited by 104
Marinello, P. C., Panis, C., da Silva, T. N. X., Binato, R., Abdelhay, E. S. F. W., Rodrigues, J. A., Mencalha, A. L., Lopes, N. M. D., Luiz, R. C., Cecchini, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42357-w · Cited by 104
MicroRNA-34a Modulates Chemosensitivity of Breast Cancer Cells to Adriamycin by Targeting Notch1
Li, X., Ji, M., Zhong, S., Zha, Q.-B., Xu, J., Zhao, J., & Tang, J. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.09.007 · Cited by 103
Verdoodt, B., Neid, M., Vogt, M., KUHN, V., Liffers, S., Palisaar, R., Noldus, J., Tannapfel, A., & Mirmohammadsadegh, A. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1915 · Cited by 103
Maryam, A., Mehmood, T., Zhang, H., Li, Y., Khan, M. N., & Ma, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-06535-y · Cited by 103
Cardioprotective effect of ascorbic acid on doxorubicin-induced myocardial toxicity in rats
Swamy, A. H. V., Wangikar, U., Koti, B., Thippeswamy, A. H. M., Ronad, P. M., & Manjula, D. V. (2011) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.84952 · Cited by 102
microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells
Zhang, W. (2011) · Oncology Reports · doi:10.3892/or.2011.1245 · Cited by 102
Januchowski, R., Sterzyńska, K., Zawierucha, P., Ruciński, M., Świerczewska, M., Partyka, M., Bednarek-Rajewska, K., Brązert, M., Nowicki, M. O., Zabel, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18278 · Cited by 102
Bouvy, C., Wannez, A., Laloy, J., Chatelain, C., & Dogné, J.-M. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.09.014 · Cited by 102
Boo, S. D., Kopecka, J., Brusa, D., Gazzano, E., Matera, L., Ghigo, D., Bosìa, A., & Riganti, C. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-108 · Cited by 101
Wu, Y., Zhang, Y., Zhang, W., Sun, C., Wu, J., & Tang, J. (2016) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.11.041 · Cited by 100
Füredi, A., Szebényi, K., Tóth, S., Cserepes, M., Hámori, L., Nagy, V., Karai, E., Vajdovich, P., Imre, T., Szabó, P., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.010 · Cited by 100
Chen, Z., Deng, Zhao, Z., & Tao, T. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s33541 · Cited by 99
Transformation of the Anticancer Drug Doxorubicin in the Human Gut Microbiome
Yan, A., Culp, E. J., Perry, J. A., Lau, J. T., MacNeil, L. T., Surette, M. G., & Wright, G. D. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00166 · Cited by 99
Chemical profiling of the genome with anti-cancer drugs defines target specificities
Pang, B., de Jong, J., Qiao, X., Wessels, L. F. A., & Neefjes, J. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1811 · Cited by 98
Xu, Y., Ohms, S., Li, Z., Wang, Q., Gong, G., Hu, Y., Mao, Z., Shannon, M. F., & Fan, J. Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082062 · Cited by 98
Zhao, L., Wang, Y., Jiang, L., He, M., Bai, X., Yu, L., & Wei, M. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0300-8 · Cited by 98
Gao, M., Miao, L., Liu, M., Li, C., Yu, C., Yan, H., Yin, Y., Wang, Y., Qi, X., & Ren, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10845 · Cited by 98
Lowery, A. R., Onishko, H. M., Hallahan, D. E., & Han, Z. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.006 · Cited by 97
Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance
Li, G., Qu, Q., Qi, T.-T., Teng, X.-Q., Zhu, H., Wang, J., Lu, Q., & Qu, J. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01974-y · Cited by 96
Tu, B., Zhu, J., Liu, S., Wang, L., Fan, Q., Hao, Y., Fan, C., & Tang, T.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.10219 · Cited by 95
Activation of human multidrug resistance-1 gene promoter in response to heat shock stress
Miyazaki, M., Kohno, K., Uchiumi, T., Tanimura, H., Matsuo, K.-I., Nasu, M., & Kuwano, M. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91248-o · Cited by 95
Chen, Y., Sun, Y., Chen, L., Xu, X., Zhang, X., Wang, B., Min, L., & Liu, W. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1403 · Cited by 93
Pajic, M., Iyer, J. K., Kersbergen, A. J., van der Burg, E., Nygren, A. O. H., Jonkers, J., Borst, P., & Rottenberg, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0041 · Cited by 93
Biswas, S., Deshpande, P. P., Perche, F., Dodwadkar, N. S., Sane, S. D., & Torchilin, V. P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.020 · Cited by 93
Cheng, C., Shi, L., Wang, X., Wang, S.-X., Wan, X.-Q., Liu, S., Wang, Y., Lü, Z., Wang, L., & Ding, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4399 · Cited by 93
Expression of multidrug resistance protein gene in patients with glioma chemotherapy
Abe, T., Mori, T., Wakabayashi, Y., Nakagawa, M., Cole, S. P. C., Koike, K., Kuwano, M., & Hori, S. (1998) · Journal of Neuro-Oncology · doi:10.1023/a:1005954406809 · Cited by 92
Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation
Forrest, R. A., Swift, L. P., Rephaeli, A., Nudelman, A., Kimura, K., Phillips, D. R., & Cutts, S. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.02.026 · Cited by 92
Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery
Xiang, D., Shigdar, S. L., Bean, A. G. D., Bruce, M. P., Yang, W. R., Mathesh, M., Wang, T., Yin, W., Tran, P. H. L., Shamaileh, H. A., et al. (2017) · Theranostics · doi:10.7150/thno.20168 · Cited by 92
Guo, B., Tam, A., Santi, S. A., & Parissenti, A. M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2790-3 · Cited by 91
Chang, L., Hu, Z., Zhou, Z., & Zhang, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491659 · Cited by 91
Yeh, P.-Y., Chuang, S., Yeh, K., Song, Y., Chang, L. L.-Y., & Cheng, A. (2004) · Oncogene · doi:10.1038/sj.onc.1207426 · Cited by 90
Shen, H., Wang, D., Li, L., Yang, S., Chen, X., Zhou, S., Zhong, S., Zhao, J., & Tang, J. (2016) · Gene · doi:10.1016/j.gene.2016.10.016 · Cited by 90
Lai, J., Yang, H., Zhu, Y., Ruan, M., Huang, Y., & Zhang, Q. (2019) · BMC Cancer · doi:10.1186/s12885-019-5798-7 · Cited by 90
Jay, S. M., Murthy, A. C., Hawkins, J. F., Wortzel, J. R., Steinhauser, M. L., Alvarez, L. M., Gannon, J., MacRae, C. A., Griffith, L. G., & Lee, R. T. (2013) · Circulation · doi:10.1161/circulationaha.113.002203 · Cited by 89
Zhang, S., Guo, N., Wan, G., Zhang, T., Li, C., Wang, Y., Wang, Y., & Liu, Y. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0540-9 · Cited by 89
Doxorubicin nanoformulations on therapy against cancer: An overview from the last 10 years
D'Angelo, N. A., Noronha, M. A., Câmara, M. C. C., Kurnik, I. S., Feng, C., Araújo, V. H. S., Santos, J. H. P. M., Feitosa, V. A., Molino, J. V. D., Rangel‐Yagui, C. D. O., et al. (2021) · Biomaterials Advances · doi:10.1016/j.msec.2021.112623 · Cited by 89
Alavi, A., Acevedo, L. M., Wang, M., & Cheresh, D. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3648 · Cited by 88
Chen, M., Shen, W., Yang, Y., Wu, X., Gu, J., & Lu, P. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22522 · Cited by 88
Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2
Kowal, J., Ni, D., Jackson, S. M., Manolaridis, I., Stahlberg, H., & Locher, K. P. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166980 · Cited by 88
Coldwell, K. E., Cutts, S. M., Ognibene, T. J., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn439 · Cited by 87
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3
Wong, R. P. C., Tsang, W. P., Chau, P. Y., Co, N. N., Tsang, T. Y., & Kwok, T. T. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0336 · Cited by 87
APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells
Stefanski, C. D., Keffler, K., McClintock, S., Milac, L., & Prosperi, J. R. (2019) · Neoplasia · doi:10.1016/j.neo.2019.09.002 · Cited by 87
Keung, E. C., Toll, L., Ellis, M., & Jensen, R. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115241 · Cited by 86
PEGylated Liposomal Doxorubicin Targeted to α5β1-Expressing MDA-MB-231 Breast Cancer Cells
Shroff, K., & Kokkoli, E. (2012) · Langmuir · doi:10.1021/la204466g · Cited by 86
Patel, K. J., Trédan, O., & Tannock, I. F. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2176-z · Cited by 86
Jirkovská, A., Jansová, H., Macková, E., Macháček, M., Hašková, P., Tichotová, L., Štěrba, M., & Šimůnek, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076676 · Cited by 86
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Ohnstad, H. O., Paulsen, E. B., Noordhuis, P., Berg, M., Lothe, R. A., Vassilev, L. T., & Myklebost, O. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-211 · Cited by 86
Pan, Y.-Z., Zhou, A., Hu, Z., & Yu, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052092 · Cited by 85
Discovery of the molecular machinery CERT for endoplasmic reticulum-to-Golgi trafficking of ceramide
Hanada, K. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-9044-z · Cited by 84
Alkylation of DNA by the Anthracycline, Antitumor Drugs Adriamycin and Daunomycin
Taatjes, D. J., Gaudiano, G., Resing, K. A., & Koch, T. H. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960519z · Cited by 84
Di, X. M., Shiu, R. P. C., Newsham, I., & Gewirtz, D. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.12.016 · Cited by 84
Guo, W., Song, Y., Song, W., Liu, Y., Liu, Z., Zhang, D., Tang, Z., & Bai, O. (2020) · Scientific Reports · doi:10.1038/s41598-020-64828-1 · Cited by 83
Cheng, X., Fan, K., Wang, L., Ying, X., Sanders, A. J., Guo, T., Xing, X., Zhou, M., Du, H., Hu, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2272-z · Cited by 82
Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia
Dorr, R. T., Karanes, C., Spier, C. M., Grogan, T. M., Greer, J. P., Moore, J., Weinberger, B., Schiller, G. J., Pearce, T. E., Litchman, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1589 · Cited by 81
Fracasso, G., Falvo, E., Colotti, G., Fazi, F., Ingegnere, T., Amalfitano, A., Doglietto, G. B., Alfieri, S., Boffi, A., Morea, V., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.010 · Cited by 81
Self-citationSesărman, A., Tefas, L. R., Sylvester, B., Licărete, E., Rauca, V. F., Lupuţ, L., Pătraș, L., Porav, A. S., Banciu, M., & Porfire, A. S. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-00598-8 · Cited by 81
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance
McCubrey, J. A., Abrams, S. L., Ligresti, G., Misaghian, N., Wong, E. W. T., Steelman, L. S., Bäsecke, J., Troppmair, J., Libra, M., Nicoletti, F., et al. (2008) · Leukemia · doi:10.1038/leu.2008.207 · Cited by 80
Montaigne, D., Marechal, X., Préau, S., Baccouch, R., Modine, T., Fayad, G., Lancel, S., & Nevière, R. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.06.001 · Cited by 79
Takwi, A., Wang, Y.-M., Wu, J., Michaelis, M., Cinatl, J., & Chen, T.-S. (2013) · Oncogene · doi:10.1038/onc.2013.330 · Cited by 79
Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin
Khan, F. M., Saleh, E., Alawadhi, H., Harati, R., Zimmermann, W., & El‐Awady, R. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1394544 · Cited by 79
Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy
Paskeh, M. D. A., Saebfar, H., Mahabady, M. K., Orouei, S., Hushmandi, K., Entezari, M., Hashemi, M., Aref, A. R., Hamblin, M. R., Ang, H. L., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120463 · Cited by 79
Olson, R. D., Gambliel, H. A., Vestal, R. E., Shadle, S. E., Charlier, H. A., & Cusack, B. J. (2005) · Cardiovascular Toxicology · doi:10.1385/ct:5:3:269 · Cited by 78
Ta, T., Bartolak‐Suki, E., Park, E.-J., Karrobi, K., McDannold, N. J., & Porter, T. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.08.013 · Cited by 77
Shen, H., Li, L., Yang, S., Wang, D., Zhong, S., Zhao, J., & Tang, J. (2016) · Gene · doi:10.1016/j.gene.2016.08.016 · Cited by 77
Lee, J., Guan, W., Han, S., Hong, D., Kim, L.-S., & Kim, H. (2018) · Cancer Science · doi:10.1111/cas.13588 · Cited by 77
Obexer, P., Hagenbuchner, J., Unterkircher, T., Sachsenmaier, N., Seifarth, C., Böck, G., Porto, V., Geiger, K., & Ausserlechner, M. J. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-07-0699 · Cited by 76
Xu, H., Hu, M., Xiu, Y., Li, Y., Fu, Y., Zhou, X., Zhang, D., & Li, J. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.030 · Cited by 76
Januchowski, R., Zawierucha, P., Ruciński, M., Andrzejewska, M., Wojtowicz, K., Nowicki, M. O., & Zabel, M. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.02.002 · Cited by 76
Nesher, E., Safina, A. F., Aljahdali, I. A. M., Portwood, S. M., Wang, E. S., Koman, I. E., Wang, J., & Gurova, K. V. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2690 · Cited by 76
Gogolin, S., Ehemann, V., Becker, G., Brueckner, L. M., Dreidax, D., Bannert, S., Nolte, I. J. A., Savelyeva, L., Bell, E., & Westermann, F. (2013) · Cell Cycle · doi:10.4161/cc.24091 · Cited by 75
Dicheva, B. M., ten Hagen, T. L. M., Schipper, D., Seynhaeve, A. L. B., van Rhoon, G. C., Eggermont, A. M. M., & Koning, G. A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.058 · Cited by 74
Cancer Stem Cell Epigenetics And Chemoresistance
Crea, F., Danesi, R., & Farrar, W. L. (2009) · Epigenomics · doi:10.2217/epi.09.4 · Cited by 74
Zheng, Z., Liu, J., Yang, Z., Wu, L., Xie, H., Jiang, C., Lin, B.-Y., Chen, T., Xing, C., Liu, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8584 · Cited by 74
Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2
Rong, Y., Yuan, C.-H., Qu, Z., Zhou, H., Guan, Q., Yang, N., Leng, X., Bu, L., Wu, K., & Wang, F.-B. (2016) · Scientific Reports · doi:10.1038/srep23824 · Cited by 74
Kessler, S. M., Pokorny, J., Zimmer, V., Laggai, S., Lammert, F., Bohle, R. M., & Kiemer, A. K. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00005.2012 · Cited by 73
Kim, D. Y., Park, E. Y., Chang, E., Kang, H.-G., Koo, Y., Lee, E. J., Ko, J. Y., Kong, H. K., Chun, K., & Park, J. H. (2016) · Oncotarget · doi:10.18632/oncotarget.7443 · Cited by 73
Wennerberg, E., Sarhan, D., Carlsten, M., Kaminskyy, V. O., D’Arcy, P., Zhivotovsky, B., Childs, R. W., & Lundqvist, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28163 · Cited by 72
Magic ferritin: A novel chemotherapeutic encapsulation bullet
Şimşek, E., & Kilic, M. A. (2005) · Journal of Magnetism and Magnetic Materials · doi:10.1016/j.jmmm.2005.01.066 · Cited by 72
Wang, C., Ke, S., Li, M., Lin, C., Liu, X., & Pan, Q. (2019) · Molecular Genetics and Genomics · doi:10.1007/s00438-019-01620-5 · Cited by 72
Novak, A. J., Asmann, Y. W., Maurer, M. J., Wang, C., Slager, S. L., Hodge, L. S., Manske, M. K., Price-Troska, T. L., Yang, Z.-Z., Zimmermann, M. T., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.69 · Cited by 70
Rebbaa, A., Chu, F., Davis, F. B., Davis, P. J., & Mousa, S. A. (2008) · Angiogenesis · doi:10.1007/s10456-008-9110-8 · Cited by 70
Graeser, R., Esser, N., Unger, H., Fichtner, I., Zhu, A., Unger, C., & Kratz, F. (2009) · Investigational New Drugs · doi:10.1007/s10637-008-9208-2 · Cited by 70
LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway
Wang, X., Liu, Y., Fan, Y.-X., Liu, Z., Yuan, Q., Jia, M., Geng, Z., Gu, L., & Lu, X. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1449610 · Cited by 70
Du, F., Yu, L., Wu, Y., Wang, S., Yao, J., Zheng, X., Xie, S., Zhang, S., Lu, X., Liu, Y., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2164-2 · Cited by 70
Taking advantage of cellular uptake of ferritin nanocages for targeted drug delivery
Tesařová, B., Musílek, K., Rex, S., & Heger, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.026 · Cited by 70
YAMASHITA, M., WADA, H., Eguchi, H., Ogawa, H., Yamada, D., Noda, T., Asaoka, T., Kawamoto, K., Gotoh, K., Umeshita, K., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3496 · Cited by 69
Metadata
- Authors
- Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2023-10
- Volume
- 93
- Pages
- 101205
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W4385325206
- Cited by
- 294
- References
- 587
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.